Lorlatinib

Contraindicated

Lorlatinib Encorafenib Braftovi Reduced encorafenib exposure, reduced lorlatinib exposure and an increased risk of serious hepatotoxicity Details

Major

Lorlatinib Acetaminophen And Codeine Capital® & Codeine Explained Reduced codeine and morphine exposure, reduced opioid efficacy and precipitation of opioid withdrawal Details Lorlatinib Abametapir Explained Increased exposure of CYP3A4 substrate Details Lorlatinib Buprenorphine Belbuca Explained Reduced buprenorphine exposure and reduced efficacy of buprenorphine Details Lorlatinib Simvastatin Flolipid Explained Decreased exposure of the CYP3A substrate Details Lorlatinib Acalabrutinib Calquence Decreased exposure of the CYP3A substrate Details Lorlatinib Atogepant Qulipta Reduced atogepant exposure Details Lorlatinib Avapritinib Ayvakit Reduced avapritinib exposure and reduced efficacy of avapritinib Details Lorlatinib Cariprazine Vraylar Explained Effects on the cariprazine exposure has not been evaluated and the net effect is unclear Details Lorlatinib Aficamten Reduced aficamten exposure and reduced efficacy of aficamten Details Lorlatinib Amlodipine Amvaz® Reduced amLODIPine exposure Details Lorlatinib Axitinib Inlyta Reduced CYP3A substrates exposure and reduced efficacy of CYP3A4 substrates Details Lorlatinib Bedaquiline Sirturo Reduced bedaquiline exposure and reduced efficacy of bedaquiline Details Lorlatinib Bosutinib Bosulif Reduced CYP3A substrates exposure and reduced efficacy of CYP3A4 substrates Details Lorlatinib Brigatinib Alunbrig Decreased brigatinib exposure and efficacy Details Lorlatinib Cabozantinib Cabometyx Reduced cabozantinib exposure and reduced efficacy of cabozantinib Details Lorlatinib Cabozantinib (Thyroid Cancer) Cabometyx Reduced cabozantinib exposure and reduced efficacy of cabozantinib Details Lorlatinib Capmatinib Tabrecta Decreased capmatinib exposure and reduction of antitumor activity Details Lorlatinib Clindamycin Injection ANTIROBE Reduced CYP3A substrates exposure and reduced efficacy of CYP3A4 substrates Details Lorlatinib Clindamycin Topical C/T/S® Reduced CYP3A substrates exposure and reduced efficacy of CYP3A4 substrates Details Lorlatinib Clindamycin Vaginal Cleocin Reduced CYP3A substrates exposure and reduced efficacy of CYP3A4 substrates Details Lorlatinib Cobimetinib Cotellic Reduced CYP3A substrates exposure and reduced efficacy of CYP3A4 substrates Details Lorlatinib Cyclosporine Injection Atopica Reduced P-gp and CYP3A4 substrates exposure and reduced efficacy of P-gp and CYP3A4 substrates Details Lorlatinib Cyclosporine Ophthalmic Cequa Reduced P-gp and CYP3A4 substrates exposure and reduced efficacy of P-gp and CYP3A4 substrates Details Lorlatinib Dabigatran Pradaxa® Reduced dabigatran exposure, reduced efficacy of dabigatran and an increased risk of thrombosis Details Lorlatinib Dabigatran Etexilate Reduced dabigatran exposure, reduced efficacy of dabigatran and an increased risk of thrombosis Details Lorlatinib Dasatinib Phyrago Reduced CYP3A substrates exposure and reduced efficacy of CYP3A4 substrates Details Lorlatinib Digoxin Cardoxin® Reduced digoxin exposure and reduced efficacy of digoxin Details Lorlatinib Dihydroergotamine Injection DHE-45® Injection Reduced CYP3A substrates exposure and reduced efficacy of CYP3A4 substrates Details Lorlatinib Dihydroergotamine Nasal Spray Migranal Reduced CYP3A substrates exposure and reduced efficacy of CYP3A4 substrates Details Lorlatinib Docetaxel Beizray Reduced CYP3A substrates exposure and reduced efficacy of CYP3A4 substrates Details Lorlatinib Docetaxel Injection Beizray Reduced CYP3A substrates exposure and reduced efficacy of CYP3A4 substrates Details Lorlatinib Dofetilide Tikosyn Reduced CYP3A substrates exposure and reduced efficacy of CYP3A4 substrates Details Lorlatinib Doravirine Pifeltro Reduced doravirine exposure and reduced efficacy of doravirine Details Lorlatinib Elacestrant Orserdu Reduced elacestrant exposure and reduced efficacy of elacestrant Details Lorlatinib Entrectinib Rozlytrek Reduced entrectinib exposure and reduced efficacy of entrectinib Details Lorlatinib Erdafitinib Balversa Reduced erdafitinib exposure Details Lorlatinib Estradiol Delestrogen Reduced hormonal contraceptive exposure, reduced efficacy of hormonal contraceptives and increased risk of breakthrough bleeding a... Details Lorlatinib Estradiol Topical Divigel Reduced hormonal contraceptive exposure, reduced efficacy of hormonal contraceptives and increased risk of breakthrough bleeding a... Details Lorlatinib Estradiol Transdermal Patch Alora® Reduced hormonal contraceptive exposure, reduced efficacy of hormonal contraceptives and increased risk of breakthrough bleeding a... Details